prostaglandin biosynthesis Inhibitors
2 drugsAbout prostaglandin biosynthesis
Prostaglandin biosynthesis is the process by which prostaglandins are created, hormone-like lipid compounds mediating inflammation, pain, and fever. Inhibiting this process is a therapeutic strategy to alleviate these symptoms.
Prostaglandin biosynthesis is a target for pain management, evidenced by two FDA-approved drugs. Currently, there is no genetic evidence available linking prostaglandin biosynthesis directly to specific diseases.
Two small molecule drugs, ACULAR and ACUVAIL (both AbbVie), target prostaglandin biosynthesis. One drug is used in pain, and the other in an 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Shoulder Pain with only 2 trials.
Top prostaglandin biosynthesis Drugs
AbbVie is the only company with approved drugs targeting prostaglandin biosynthesis.
High market concentration suggests potential entry barriers or partnering opportunities with AbbVie.
prostaglandin biosynthesis Drug Modality Landscape
Modalities
Routes of Administration
prostaglandin biosynthesis is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or biologics could create differentiation.
prostaglandin biosynthesis Clinical Trials 170 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 8 | 5 | 2 | 62% |
| Phase 2 | 44 | 28 | 10 | 5 | 74% |
| Phase 3 | 32 | 19 | 3 | 9 | 86% |
| Phase 4 | 79 | 52 | 16 | 10 | 76% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
prostaglandin biosynthesis Drug Approval Timeline (1992 - 2009)
The first drug was approved in 1992 (ACULAR), and the most recent in 2009 (ACUVAIL).
The approval timeline suggests a potentially saturated market or declining interest in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 140 clinical trials targeting prostaglandin biosynthesis.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities